X4 Pharmaceuticals
XFOR
53 hedge funds and large institutions have $69.3M invested in X4 Pharmaceuticals in 2020 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 18 increasing their positions, 18 reducing their positions, and 8 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
0% more repeat investments, than reductions
Existing positions increased: 18 | Existing positions reduced: 18
0.17% less ownership
Funds ownership: 2.28% → 2.11% (-0.17%)
7% less funds holding
Funds holding: 57 → 53 (-4)
32% less capital invested
Capital invested by funds: $102M → $69.3M (-$32.2M)
50% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 8
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
IC
Ikarian Capital
Dallas,
Texas
|
+$5.75M |
| 2 |
BFM
Boothbay Fund Management
New York
|
+$613K |
| 3 |
OM
Opaleye Management
Boston,
Massachusetts
|
+$599K |
| 4 |
Renaissance Technologies
New York
|
+$425K |
| 5 |
Ensign Peak Advisors
Salt Lake City,
Utah
|
+$272K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$5.27M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$3.8M |
| 3 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$1.76M |
| 4 |
BI
BVF Inc
San Francisco,
California
|
-$1.74M |
| 5 |
LGM
Logos Global Management
San Francisco,
California
|
-$1.48M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
51
Federated Hermes
Pittsburgh,
Pennsylvania
| $1K | -$479 | -2 | -50% |
|
|
SFM
52
Sphera Funds Management
Tel Aviv,
Israel
| – | -$5.27M | -18,860 | Closed |
|
|
CAM
53
Cormorant Asset Management
Boston,
Massachusetts
| – | -$1.76M | -10,966 | Closed |
|
|
LGM
54
Logos Global Management
San Francisco,
California
| – | -$1.48M | -5,283 | Closed |
|
|
CWM
55
Centric Wealth Management
Chicago,
Illinois
| – | -$363K | -1,298 | Closed |
|
|
MAM
56
Martingale Asset Management
Boston,
Massachusetts
| – | -$236K | -844 | Closed |
|
57
Bessemer Group
Woodbridge,
New Jersey
| – | -$171K | -613 | Closed |
|
|
CAN
58
Cetera Advisor Networks
El Segundo,
California
| – | -$47K | -167 | Closed |
|
59
Barclays
London,
United Kingdom
| – | -$1K | -5 | Closed |
|
60
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | +$240 | +1 | New |
|
XFOR Hedge Fund Activity: Q3 2020 in Review
53 of the 4,956 institutional investors tracked by Wall St. Rank reported a position in X4 Pharmaceuticals (XFOR) for Q3 2020, worth a combined $69.3M — down 32% from $102M a quarter earlier.
Sellers outnumbered buyers: 8 funds closed out of XFOR and 4 opened new positions — a net loss of 4 holders — while 18 trimmed existing stakes and 18 added.
The largest buyer was Ikarian Capital, adding an estimated $5.75M. The largest seller was Sphera Funds Management, exiting entirely with an estimated $5.27M sold.
- 53 institutional investors held X4 Pharmaceuticals (XFOR) as of Q3 2020, down from 57 in Q2 2020.
- Funds reported $69.3M of X4 Pharmaceuticals stock for Q3 2020, down 32% quarter-over-quarter.
- 4 funds opened new X4 Pharmaceuticals positions in Q3 2020 and 8 closed out, a net change of -4 holders.
- The largest X4 Pharmaceuticals buyer in Q3 2020 was Ikarian Capital, an estimated $5.75M added.
- The largest X4 Pharmaceuticals seller in Q3 2020 was Sphera Funds Management, an estimated $5.27M sold.
Based on aggregated 13F filings for Q3 2020.